Nektar Therapeutics (NKTR)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
As of 02:37PM EDT. Market open.
| Previous close | 1.3200 |
| Open | 1.3300 |
| Bid | 1.3100 x 200 |
| Ask | 1.3300 x 5000 |
| Day's range | 1.3100 - 1.3800 |
| 52-week range | 0.4100 - 1.7500 |
| Volume | |
| Avg. volume | 2,551,675 |
| Market cap | 241.458M |
| Beta (5Y monthly) | 0.91 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 28, 2024 at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time.
- PR Newswire
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata
Nektar Therapeutics (Nasdaq: NKTR), a biotechnology company developing medicines for the treatment of auto-immune disorders, today announced the initiation of its Phase 2b clinical trial evaluating rezpegaldesleukin in patients with severe to very severe alopecia areata.
- PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter and full year ended December 31, 2023.
© 2024 Yahoo. All rights reserved.